Cardiac biomarkers in dialysis

AIMS Genet. 2016 Dec 26;4(1):1-20. doi: 10.3934/genet.2017.1.1. eCollection 2017.


Cardiovascular disease is the major cause of death, accounting for approximately 40 percent of all-cause mortality in patients receiving either hemodialysis or peritoneal dialysis. Cardiovascular risk stratification is an important aspect of managing dialysis patients as it enables early identification of high-risk patients, so therapeutic interventions can be optimized to lower cardiovascular morbidity and mortality. Biomarkers can detect early stages of cardiac injury so timely intervention can be provided. The B-type natriuretic peptides (Brain Natriuretic peptide [BNP] and N-terminal pro-B-type natriuretic peptide [NT-proBNP]) and troponins have been shown to predict mortality in dialysis patients. Suppression of tumorigenicity 2 (ST2) and galectin-3 are new emerging biomarkers in the field of heart failure in both the general and dialysis populations. This article aims to discuss the current evidence regarding cardiac biomarker use to diagnose myocardial injury and monitor the risk of major adverse cardiovascular events in patients undergoing dialysis.

Keywords: Biomarkers; Cardiovascular disease; Chronic kidney disease; Dialysis; Galectin; Hemodialysis; N-terminal pro-B-type natriuretic peptide; Natriuretic peptide; Suppression of tumorigenicity 2; Troponin; brain.

Publication types

  • Review